Hospital Israelita Albert Einstein
einstein.brTotal trials
145
Active
32
Phase 3
18
Total enrollment
2,253,634
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 12 of 12 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel | — | — | — | — | — | 1 | |
| Monotherapy: Ticagrelor alone OR Prasugrel alone | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| ATG | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 2 | |
| Plerixafor Dose Escalation | — | — | — | — | — | 1 | |
| Nivolumab 40 mg in 4 ml | — | — | — | — | — | 1 | |
| Ipilimumab 200 MG in 40 ML | — | — | — | — | — | 1 | |
| Lymphocyte | — | — | — | — | — | 1 | |
| Intensive Control of Systolic Blood Pressure | — | — | — | — | — | 2 | |
| Standard control of Systolic Blood Pressure | — | — | — | — | — | 2 | |
| Standard Pain Management | — | — | — | — | — | 1 |
Next readouts
- 2021-11-01
- 2025-05-30
- 2025-06-10
- 2025-12-15
- 2026-05-28
- 2026-05-31
- 2026-12-31
- 2027-12
- 2028-12
- 2028-12
Top conditions
- Hypertension5
- Emotional Stress5
- Cardiovascular Diseases4
- Stroke3
- Acute Coronary Syndrome3
- Covid193
- Sepsis3
- Cancer3
Frequently asked questions about Hospital Israelita Albert Einstein
- How many clinical trials does Hospital Israelita Albert Einstein have on ClinicalTrials.gov?
- Hospital Israelita Albert Einstein is listed as the lead sponsor on 145 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hospital Israelita Albert Einstein's trials are in Phase 3?
- 18 of Hospital Israelita Albert Einstein's trials are in Phase 3, spread across 12 active drug programs.
- What therapeutic areas does Hospital Israelita Albert Einstein focus on?
- Hospital Israelita Albert Einstein's most-studied conditions on ClinicalTrials.gov are Hypertension, Emotional Stress, Cardiovascular Diseases, Stroke, Acute Coronary Syndrome.
- When are Hospital Israelita Albert Einstein's next clinical trial readouts?
- Hospital Israelita Albert Einstein has 10 upcoming primary-completion readouts tracked here; the soonest is “Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies”, expected around 2021-11-01.